Strong revenue growth and product innovations have Wall Street believing that this growth stock will rally 114% over the next 12 months.
This growth stock has tumbled in recent months, but analysts are forecasting more than 100% upside, based on Wall Street's mean price target.
Growth stocks such as Viking Therapeutics, Cresco Labs, and Alphatec Holdings continue to trade at a significant discount to analysts' consensus price target estimates.
Alphatec's revenue growth could lead to the company becoming profitable, causing the stock to rally. However, there are risks.
The spine surgery solutions company fell after pricing a $150 million public offering of common stock. Here's what investors need to know.
Alphatec's strong revenue growth makes it worth watching.